Clinical Trials: Melanoma

Birmingham :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Birmingham : GSK Investigational Site

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Scottsdale : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Scottsdale : Mayo Clinic Arizona - Cancer Clinical Research Unit

A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers

Scottsdale : Oncology Research Associates, Pllc D/B/A

Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma

Scottsdale : TGen Clinical Research Service at Scottsdale Healthcare

Safety Study of PLX108-01 in Patients With Solid Tumors

Scottsdale : Call for Information (Investigational Site 0004)

Study of MK-3475 in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM6)

View More »

Tucson : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Tucson : University of Arizona Cancer Center

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

Tucson : Arizona Clinical Research

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

Tucson :

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

Little Rock : University of Arkansas for Medical Sciences

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

Beverly Hills : Beverly Hill Cancer Center

Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma

Beverly Hills : Call for Information (Investigational Site 0061) Updated

Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)

Concord :

A Study of Vemurafenib Alone And Vemurafenib in Combination With GDC-0973 in Patients With Malignant Melanoma

Encinitas :

A Study of Vemurafenib Alone And Vemurafenib in Combination With GDC-0973 in Patients With Malignant Melanoma

Encinitas : San Diego Pacific Oncology and Hematology Associates, Inc.

Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma

View More »

La Jolla : Moores UCSD Cancer Center

A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma

La Jolla : Moores UCSD Cancer Center

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

La Jolla :

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

Los Angeles :

A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With INCB024360 or Placebo in Subjects With Unresectable or Metastatic Melanoma

Los Angeles :

A Study of The Safety and Pharmacology of MPDL3280A Administered in Combination With Vemurafenib (Zelboraf®) in Patients With Previously Untreated BRAFV600-Mutation Positive Metastatic Melanoma

Los Angeles :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Los Angeles :

A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma

Los Angeles :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Los Angeles : University of California Los Angeles

Combination of Temozolomide and Sunitinib in Treatment of Patients With Metastatic and Unresectable Malignant Melanoma

Los Angeles : GSK Investigational Site

Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma

Los Angeles : USC Norris Cancer Center

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

Los Angeles : University of California, Los Angeles

Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma

Los Angeles : UCLA

Safety Study of PLX108-01 in Patients With Solid Tumors

Los Angeles : The Angeles Clinic and Research Institute

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

Los Angeles : The Angeles Clinic and Research Institute

Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma

Los Angeles : Call for Information (Investigational Site 0010)

Study of MK-3475 in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM6)

Los Angeles : Call for Information (Investigational Site 0015)

Study of MK-3475 in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM6)

Los Angeles :

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

Orange : Chao Family Comprehensive Cancer Center

Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma

San Diego : Rady Children's Hospital

Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma

San Francisco : St Mary's Medical Center

A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma

San Francisco :

A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma

San Francisco : University of California, San Francisco

BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma

San Francisco : GSK Investigational Site

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

San Francisco : Northern California Melanoma Center/ St. Mary's Medical Center

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

San Francisco : Call for Information (Investigational Site 0008)

Study of MK-3475 in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM6)

San Francisco : UCSF Helen Diller Comprehensive Cancer Center

Trial of pIL-12 Electroporation Malignant Melanoma

Santa Monica :

A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma

Santa Monica : The Angeles Clinic

Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma

Santa Monica :

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

Santa Monica : John Wayne Cancer Institute

Trial of pIL-12 Electroporation Malignant Melanoma

Stanford : Stanford Cancer Center - Stanford University

A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers

Temecula : Pacific Dermatology Institute

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

Vallejo : GSK Investigational Site

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Aurora :

A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma

Aurora :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Aurora : University of Colorado Cancer Center

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

Aurora : Anschutz Cancer Pavilion

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

Aurora :

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

View More »

Denver : University of Colorado, Denver

Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma

Denver : Rocky Mountain Cancer Centers

Safety Study of PLX108-01 in Patients With Solid Tumors

Hamden : New England Retina Associates

Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)

New Haven : Yale University School Of Medicine

Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma

Washington : The Melanoma Center at the Washington Cancer Institute

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

Washington : MedStar Clinical Research Ctr at Washington Hospital Center

Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma

Tampa : H. Lee Moffitt Cancer Center

A Phase 1/2 study of PX-866 and Vemurafenib in Patients with Advanced Melanoma

View More »

Fort Myers : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Jacksonville : GSK Investigational Site

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Jacksonville : Baptist Cancer Institute

Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma

Jacksonville : Call for Information (Investigational Site 0003)

Study of MK-3475 in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM6)

Lakeland : Lakeland Regional Cancer Center

Trial of pIL-12 Electroporation Malignant Melanoma

Miami Beach : Research Site

A Phase 1 Study to Evaluate MEDI4736

Miami Beach : Mount Sinai Medical Center

A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma

Miami Beach : MSMC Research Program

HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma

Miami Beach : Mount Sinai Medical Center Comprehensive Cancer Center

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

Miami Beach : Mount Sinai Medical Center

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

Orlando : GSK Investigational Site

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Orlando : MD Anderson Cancer Center Orlando

Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma

Orlando : MD Anderson Cancer Center-Orlando

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

Ormond Beach : Ameriderm Research

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

Tampa : Research Site

A Phase 1 Study to Evaluate MEDI4736

Tampa :

A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With INCB024360 or Placebo in Subjects With Unresectable or Metastatic Melanoma

Tampa : H. Lee Moffitt Cancer Center/University of South Florida Moffitt SC

A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma

Tampa : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Tampa :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Tampa : Moffitt Cancer Center

Evaluate Safety/Tolerability Intra-Arterial Temozolomide in Patients w/Extremity Melanoma by Isolated Limb Infusion

Tampa : H. Lee Moffitt Cancer Center and Research Institute

Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts

Tampa : H. Lee Moffitt Cancer Center and Research Institute

Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558

Tampa : H. Lee Moffitt Cancer Center and Research Institute

Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 Antibody BMS936558

Tampa : H. Lee Moffitt Cancer Center and Research Institute

Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC

Tampa : Call for Information (Investigational Site 0018)

Study of MK-3475 in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM6)

Tampa : H. Lee Moffitt Cancer Center

Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma

Tampa : H. Lee Moffitt Cancer Center and Research Institute

Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma

Tampa :

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

Tampa : H. Lee Moffitt Cancer Center and Research Institute

Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma

West Palm Beach : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Augusta : Research Site

A Phase 1 Study to Evaluate MEDI4736

Elgin : Sherman Health

ECOG E1609 Phase III Randomized Study of Adjuvant Ipilimumab Versus High-Dose Recombinant Interferon Alfa-2b in Patients With High-Risk Stage IIIB, IIIC, or IV Melanoma

View More »

Chicago : Rush University Medical Center

A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma

Chicago :

A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma

Chicago : Rush Pres St Lukes Medical Center

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

Chicago : Robert H. Lurie Comprehensive Cancer Center, Northwestern University

Safety, Tolerability, and Preliminary Efficacy Study of ALS-357 in Patients With Cutaneous Metastatic Melanoma

Chicago : University of Chicago

Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma

Maywood : Loyola University Medical Center

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

Niles : Oncology Specialists, SC

A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma

Niles : Oncology Specialists, SC (OSSC)

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

Park Ridge :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Park Ridge : Oncology Specialists, SC

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

Park Ridge :

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

Goshen :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Goshen : Indiana University Health Goshen Center for Cancer Care

Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma

Indianapolis :

A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma

Indianapolis : Indiana University Melvin and Bren Simon Center

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

Indianapolis : Indiana University - Simon Cancer Center

Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma

View More »

Indianapolis : Indiana University Melvin And Bren Simon Cancer Center

Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma

Indianapolis : Investigative Clinical Research of Indiana

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

Iowa City :

A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma

Iowa City : University of Iowa Hospitals and Clinics

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

Iowa City : University of Iowa Hospitals and Clinics

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

Iowa City : University of Iowa Hospitals and Clinics

Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat

Lexington : Central Kentucky Research Associates

Melanoma Vaccine

View More »

Lexington : Central Baptist Hospital

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

Lexington : Central Kentucky Research Associates

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

Louisville : James Graham Brown Cancer Center

Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma

Louisville : University of Louisville Hospital

Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma

Baton Rouge : The Baton Rouge Clinic, AMC

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

Baltimore : Weinberg Cancer Institution at Franklin Square

Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma

Boston : Massachusetts General Hospital Mass General 2

A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma

Boston : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Boston :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Boston : Dana-Farber Cancer Institute

An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma

Boston : Beth Israel Deaconess Medical Center

An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma

View More »

Boston : Massachusetts General Hospital

An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma

Boston : Dana Farber Cancer Institute

Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma

Boston : Dana Farber Cancer Institute

Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma

Boston : Beth Israel Deaconess Medical Center

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

Boston : Massachusetts Eye & Ear Infirmary

Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma

Boston : Dana Farber Cancer Institute DFCI - Brookline

Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients

Boston : Massachusetts General Hospital Cancer Center

Safety Study of MGA271 in Refractory Cancer

Boston : Beth Israel Deaconess Medical Center

Safety Study of PLX108-01 in Patients With Solid Tumors

Boston : Dana Farber Cancer Institute

Safety Study of PLX108-01 in Patients With Solid Tumors

Boston : Massachusetts General Hospital

Safety Study of PLX108-01 in Patients With Solid Tumors

Boston : Dana-Farber Cancer Institute

STA-9090(Ganetespib) in Metastatic Ocular Melanoma

Boston : Massachusetts General Hospital

STA-9090(Ganetespib) in Metastatic Ocular Melanoma

Boston : Dana-Farber Cancer Institute

STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma

Boston : Call for Information (Investigational Site 0011)

Study of MK-3475 in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM6)

Boston : Dana-Farber Cancer Institute

SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma

Boston : Massachusetts General Hospital

SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma

Boston : Beth Israel Deaconess Medical Center

SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma

Boston : Massachusetts General Hospital

Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors

Rockland, MA for US Recruiting Sites : Please contact the US Medical Information in

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Detriot : Wayne State University Karmanos Cancer Institute

Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies

Detroit : Wayne State University/Karmanos Cancer Institute Wayne St

A Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands

Detroit :

A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma

Detroit :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Detroit : Barbara Ann Karmanos Cancer Institute

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

View More »

Detroit : Henry Ford Medical Center

Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma

Minneapolis : University of Minnesota Masonic Cancer Center

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

Rochester : Mayo Clinic

A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers

Rochester :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Rochester : Mayo Clinic Cancer Center, Mayo Clinic Rochester

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

Rochester : Call for Information (Investigational Site 0002)

Study of MK-3475 in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM6)

Kansas City : Center for Pharmaceutical Research

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

St Louis :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

St. Louis : GSK Investigational Site

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

St. Louis : GSK Investigational Site

Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma

St. Louis : Washington University in St. Louis

Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma

View More »

St. Louis : Washington University School of Medicine

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

St. Louis : St. Louis Hospital

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

St. Louis :

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

St. Louis : Washington University in St. Louis

SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma

Lincoln : Southeast Nebraska Hematology & Oncology Consultants, Lincol

Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma

Omaha : Midwest Cancer Center - Legacy

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

Las Vegas :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Las Vegas : Comprehensive Cancer Centers of Nevada

Culture and Characterization of Circulating Tumor Cells (CTC) in Melanoma and Other Cancers

Las Vegas : GSK Investigational Site

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Las Vegas : Comprehensive Cancer Centers of Nevada

Safety Study of PLX108-01 in Patients With Solid Tumors

Lebanon : Dartmouth-Hitchcock Medical Center

HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma

Lebanon : Dartmouth Hitchcock Medical Center

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

Lebanon : Norris Cotton Cancer Center / Dartmouth-Hitchcock Medical Center

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

Hackensack : GSK Investigational Site

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Hackensack : John Theurer Cancer Center

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

Morristown : Atlantic Melanoma Center

A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma

Morristown : Atlantic Melanoma Center

Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma

New Brunswick : Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School

Effects of Monoclonal Antibody GC1008 in Blood Samples From Patients With Unresectable Locally Advanced or Metastatic Kidney Cancer or Malignant Melanoma Treated on Clinical Trial NCI-06-C-0200

View More »

New Brunswick : Cancer Center of NJ

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

Princeton : GE Healthcare Office

A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis

Randolph :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Albuquerque : New Mexico Cancer Care Alliance

Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma

New York : New York University

A Phase 1/2 study of PX-866 and Vemurafenib in Patients with Advanced Melanoma

View More »

Bronx : Saint Luke's-Roosevelt Hospital Center

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

Buffalo : Roswell Park Cancer Institute

Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies

New York : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

New York :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

New York :

A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma

New York : Memorial Sloan Kettering Cancer Center

Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity

New York : Memorial Sloan Kettering Cancer Center

Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation

New York : New York University Langone Clinical Cancer Center

CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma

New York : Memorial Sloan Kettering Cancer Center

Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma

New York : Mount Sinai

Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma

New York : Memorial Sloan-Kettering Cancer Center

RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma

New York : Memorial Sloan Kettering Cancer Center MSKCC 4

Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients

New York : Memorial Sloan-Kettering Cancer Center (MSKCC)

Safety Study of PLX108-01 in Patients With Solid Tumors

New York : Mount Sinai School of Medicine

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

New York : Call for Information (Investigational Site 0019)

Study of MK-3475 in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM6)

New York : New York University

Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma

New York :

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

New York : Melanoma and Sarcoma Service / Memorial Sloan Kettering Cancer Center

Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors

New York : Memorial Sloan-Kettering Cancer Center

Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation

Chapel Hill : Lineberger Comprehensive Cancer Center, University of North Carolina

LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations

Charlotte :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Charlotte : Blumenthal Cancer Center

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

Durham : GSK Investigational Site

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Durham : Duke University Medical Center

Evaluate Safety/Tolerability Intra-Arterial Temozolomide in Patients w/Extremity Melanoma by Isolated Limb Infusion

View More »

Durham : Duke University Medical Center

Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma

Durham : Duke University Medical Center

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

Durham : Call for Information (Investigational Site 0036) Updated

Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)

Raleigh : Wake Research Associates

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

Winston Salem : Wake Forest University Baptist Medical Center

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

Winston-Salem : Wake Forest University School of Medicine, Comprehensive Cancer Center

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

Cincinnati : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Cincinnati : GSK Investigational Site

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Cleveland : University Hospitals Siedman Cancer Center

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

Columbus : The Ohio State University Comprehensive Cancer Center

A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers

Portland : Providence Cancer Center

Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma.

Portland : GSK Investigational Site

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Portland : Providence Portland Medical Center

Phase 1 Biomarker Study of Anti-PD-1 in Advanced Melanoma

Portland : Providence Portland Medical Center

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

Portland : Portland Providence Medical Center

Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma

View More »

Portland : Kaiser Permanente Northwest

Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma

Portland : Oregon Health and Science University

Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions

Philadelphia : Oncothyreon, Inc.

A Phase 1/2 study of PX-866 and Vemurafenib in Patients with Advanced Melanoma

Pittsburgh : University of Pittsburgh Cancer Institute

A Phase 1/2 study of PX-866 and Vemurafenib in Patients with Advanced Melanoma

View More »

Bethlehem :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Bethlehem : Saint Luke's Hospital and Health Network

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

Easton : St. Luke's Hospital, Anderson Campus

HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma

Philadelphia :

A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With INCB024360 or Placebo in Subjects With Unresectable or Metastatic Melanoma

Philadelphia : Thomas Jefferson University

Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma

Philadelphia : Hospital of the University of Pennsylvania/Abramson Cancer Center

Safety Study of MGA271 in Refractory Cancer

Philadelphia : Fox Chase Cancer Center

Safety Study of PLX108-01 in Patients With Solid Tumors

Philadelphia : Pennsylvania Oncology Hematology Associates

Safety Study of PLX108-01 in Patients With Solid Tumors

Philadelphia : University of Pennsylvania

Safety Study of PLX108-01 in Patients With Solid Tumors

Philadelphia : Kimmel Cancer Center at Thomas Jefferson Univ.

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

Philadelphia : Call for Information (Investigational Site 0016)

Study of MK-3475 in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM6)

Philadelphia : Fox Chase Cancer Center

Study of MLN2480 in Patients With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Patients With Metastatic Melanoma

Philadelphia : University of Pennsylvania

Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma

Pittsburgh : University of Pittsburgh Medical Center/University of Pittsburgh Cancer Institute

Immunogenicity and Biomarker Analysis of Neoadjuvant Ipilimumab for Melanoma

Pittsburgh : Hillman Cancer Center

Melanoma Molecular Profiling Analysis

Pittsburgh :

Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma

Pittsburgh : UPMC Hillman Cancer Center

Pilot Study of IFN α2b for Melanoma Patients

Pittsburgh : Hillman Cancer Research Pavilion, Div. of Medical Oncology

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

Pittsburgh : University of Pittsburgh

Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions

Pittsburgh : Call for Information (Investigational Site 0013)

Study of MK-3475 in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM6)

Pittsburgh : University of Pittsburgh Cancer Institute

Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma

Pittsburgh :

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

Nashville : Vanderbilt-Ingram Cancer Center

A Phase 1/2 study of PX-866 and Vemurafenib in Patients with Advanced Melanoma

View More »

Chattanooga : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Memphis : St. Jude Children's Research Hospital

Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma

Memphis : St. Jude Children's Research Hospital

Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma

Nashville : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Nashville : Sarah Cannon Research Institute

A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers

Nashville :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Nashville :

A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma

Nashville : GSK Investigational Site

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Nashville : Vanderbilt-Ingram Cancer Ctr

Phase 1 Biomarker Study of Anti-PD-1 in Advanced Melanoma

Nashville : Sarah Cannon Research Institute

Safety Study of MGA271 in Refractory Cancer

Nashville : Vanderbilt-Ingram Medical Center

Safety Study of PLX108-01 in Patients With Solid Tumors

Nashville : Call for Information (Investigational Site 0033) Updated

Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)

Nashville : Vanderbilt-Ingram Cancer Center

Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma

Nashville :

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

Nashville : Vanderbilt University

SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma

Nashville : Sarah Cannon Research Institute

Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors

Dallas : Research Across America

Do You Have Melanoma?

View More »

Amarillo : Don and Sybil Harrington Cancer Center

Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma

Dallas : Mary Crowley Cancer Research Centers - Medical City

A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers

Dallas : Mary Crowley Cancer Research Centers

A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma

Dallas :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Dallas : GSK Investigational Site

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Dallas : Mary Crowley Cancer Research Centers

Phase II FANG in Advanced Melanoma

Dallas : Mary Crowley Cancer Research Center

Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma

Dallas : Texas Oncology, PA (North)

Safety Study of PLX108-01 in Patients With Solid Tumors

Dallas : Dallas Surgical Group

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

Dallas : Research Across America

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

Dallas : Mary Crowley Cancer Research Center

Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions

Dallas :

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

Dallas : Mary Crowley Cancer Research Center

Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma

Houston : UT MD Anderson Cancer Center

A Phase I/II Study of TPI 287 - Temozolomide Combination in Melanoma

Houston : MD Anderson Cancer Center/University of Texas MD Anderson 2

A Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands

Houston :

A Study of The Safety and Pharmacology of MPDL3280A Administered in Combination With Vemurafenib (Zelboraf®) in Patients With Previously Untreated BRAFV600-Mutation Positive Metastatic Melanoma

Houston : UT MD Andreson Cancer Center

GSK2118436 and GSK1120212

Houston : UT MD Anderson Cancer Center

High-dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI

Houston : UT MD Anderson Cancer Center

Ipilimumab for Uveal Melanoma

Houston : The University of Texas MD Anderson Cancer Center

Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization

Houston : The Children's Cancer Hospital at UT M.D. Anderson Cancer Center

Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma

Houston : MD Anderson Cancer Center

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

Houston : University of Texas M.D. Anderson Cancer Center

Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma

Houston : University of Texas MD Anderson Cancer Center

Safety and Efficacy Study of INGN 241 Gene Therapy in Patients With In Transit Melanoma

Houston : Call for Information (Investigational Site 0012)

Study of MK-3475 in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM6)

Houston : UT MD Anderson Cancer Center

Study of Weekly LOC-paclitaxel Injection for Melanoma

Houston : The University of Texas MD Anderson Cancer Center

Tesetaxel as Second-line Therapy for Patients With Advanced Melanoma and Normal Serum LDH

Houston : UT MD Anderson Cancer Center

Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma

San Antonio : Call for Information (Investigational Site 0001)

Study of MK-3475 in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM6)

San Antonio : The START Center

Study of MLN2480 in Patients With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Patients With Metastatic Melanoma

San Antonio : Cancer Therapy & Research Center at UTHSCSA

Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma

Murray : Intermountain Medical Center

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

Salt Lake City : Huntsman Cancer Institute

A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma

Salt Lake City : University of Utah / Huntsman Cancer Institute Huntsman

A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors

Salt Lake City : Huntsman Cancer Institute

Efficacy and Safety of Intratumoral CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks

Salt Lake City : The Huntsman Cancer Institute, University of Utah

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

Burlington : Fletcher Allen Health Care, Inc.

Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma

Charlottesville : University of Virginia

A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients

Charlottesville : University of Virginia Health System

A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers

Charlottesville : University of Virginia

Study to Assess the Safety and Immunological Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI

Norfolk : Virginia Oncology Associates

Safety Study of PLX108-01 in Patients With Solid Tumors

Norfolk : Clinical Research Associates of Tidewater

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

Seattle :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Seattle : Seattle Cancer Care Alliance

Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma

Spokane : Evergreen Hematology & Oncology

Safety Study of PLX108-01 in Patients With Solid Tumors

Morgantown : West Virginia University - Clinical Trials Research Unit

ECOG 1609 - A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon α-2b for Resected High-Risk Melanoma

Tirana :

A Study of RO5185426 in Patients With Metastatic Melanoma

Buenos Aires : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Buenos Aires : Instituto Médico Alexander Fleming

Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF vs IFN Alpha 2b in Stage IIB, IIC and III Melanoma Patients

Caba : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Caba : GSK Investigational Site

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Capital Federal : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

View More »

Capital Federal : GSK Investigational Site

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Ciudad Autonoma de Buenos Aires : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Ciudad Autónoma de Buenos Aires : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Rosario : GSK Investigational Site

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Santa Fe : GSK Investigational Site

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Adelaide : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Adelaide : Royal Adelaide Hospital

Proteasome Inhibitor NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma

Ashford Sa :

A Study of Vemurafenib Alone And Vemurafenib in Combination With GDC-0973 in Patients With Malignant Melanoma

Greenslopes : GSK Investigational Site

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Heidelberg : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

View More »

Melbourne : Novartis Investigative Site

A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma

Melbourne :

A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma

Melbourne :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Melbourne : GSK Investigational Site

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Nedlands : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Nedlands : Sir Charles Gairdner Hospital and University of Western Australia

Proteasome Inhibitor NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma

North Sydney : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

South Brisbane : GSK Investigational Site

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

South Granville : Merck Sharp & Dohme (Australia) Pty Ltd.

Study of MK-3475 in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM6)

Wentworthville :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Westmead : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Woodville South : The Queen Elizabeth Hospital

Proteasome Inhibitor NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma

Woolloongabba : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Woolloongabba : GSK Investigational Site

Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma

Linz : Local Institution

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Salzburg : Local Institution

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Vienna : Local Institution

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Wien : GSK Investigational Site

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Antwerp : Universitair Ziekenhuis Antwerpen

An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.

Brussels : Jules Bordet Institute

An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.

Brussels : Cliniques universitaires Saint-Luc, Centre du Cancer

Safety and Toxicity Study of Vaccination for Advanced Metastatic Melanoma Patients

Bruxelles : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Bruxelles :

A Study of RO5185426 in Patients With Metastatic Melanoma

View More »

Jette : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Jette : GSK Investigational Site

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Leuven : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Leuven : GSK Investigational Site

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Wilrijk :

A Study of RO5185426 in Patients With Metastatic Melanoma

Wilrijk : GSK Investigational Site

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Banja Luka :

A Study of RO5185426 in Patients With Metastatic Melanoma

Sarajevo :

A Study of RO5185426 in Patients With Metastatic Melanoma

Belo Horizonte : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Porto Alegre : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Rio de Janeiro : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Rio de Janeiro - Rj :

A Study of RO5185426 in Patients With Metastatic Melanoma

Salvador : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

View More »

Sao Paulo :

A Study of RO5185426 in Patients With Metastatic Melanoma

São Paulo : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Plovdiv :

A Study of RO5185426 in Patients With Metastatic Melanoma

Sofia :

A Study of RO5185426 in Patients With Metastatic Melanoma

Edmonton : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Edmonton : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Edmonton :

A Study of RO5185426 in Patients With Metastatic Melanoma

Halifax :

A Study of RO5185426 in Patients With Metastatic Melanoma

Hamilton : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

View More »

Hamilton :

A Study of RO5185426 in Patients With Metastatic Melanoma

Kingston : GSK Investigational Site

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Kirkland : Merck Frosst Canada Ltd.

Study of MK-3475 in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM6)

London : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

London :

A Study of RO5185426 in Patients With Metastatic Melanoma

Montreal : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Montreal : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Montreal :

A Study of RO5185426 in Patients With Metastatic Melanoma

Montreal : GSK Investigational Site

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Oshawa : GSK Investigational Site

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Ottawa :

A Study of RO5185426 in Patients With Metastatic Melanoma

Ottawa : GSK Investigational Site

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Quebec : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Quebec : GSK Investigational Site

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Quebec City :

A Study of RO5185426 in Patients With Metastatic Melanoma

Toronto : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Toronto : Novartis Investigative Site

A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors

Toronto :

A Study of RO5185426 in Patients With Metastatic Melanoma

Toronto :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Toronto : GSK Investigational Site

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Vancouver :

A Study of RO5185426 in Patients With Metastatic Melanoma

Vancouver : GSK Investigational Site

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Winnipeg :

A Study of RO5185426 in Patients With Metastatic Melanoma

Winnipeg :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Medellin :

A Study of RO5185426 in Patients With Metastatic Melanoma

Zagreb :

A Study of RO5185426 in Patients With Metastatic Melanoma

Brno :

A Study of RO5185426 in Patients With Metastatic Melanoma

Brno : GSK Investigational Site

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

Hradec Kralove :

A Study of RO5185426 in Patients With Metastatic Melanoma

Hradec Kralove : GSK Investigational Site

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

Olomouc :

A Study of RO5185426 in Patients With Metastatic Melanoma

View More »

Ostrava :

A Study of RO5185426 in Patients With Metastatic Melanoma

Praha :

A Study of RO5185426 in Patients With Metastatic Melanoma

Praha 2 : GSK Investigational Site

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

Herlev : GSK Investigational Site

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Herlev : Copenhagen University Hospital Herlev

Safety and Efficacy Study of Electrotransfer of Plasmid AMEP to Treat Advanced or Metastatic Melanoma

Guayaquil :

A Study of RO5185426 in Patients With Metastatic Melanoma

Portoviejo :

A Study of RO5185426 in Patients With Metastatic Melanoma

Helsinki :

A Study of RO5185426 in Patients With Metastatic Melanoma

Helsinki : GSK Investigational Site

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Avignon Cedex 2 : Local Institution

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Bayonne : Local Institution

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Bordeaux :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Bordeaux : Hôpital Saint-André

DNA Repair Inhibitor & Irradiation on Melanoma

Bordeaux : GSK Investigational Site

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

View More »

Boulogne-Billancourt : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Boulogne-Billancourt : Hôpital Ambroise Paré

DNA Repair Inhibitor & Irradiation on Melanoma

Brest Cedex : Local Institution

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Courbevoie : Laboratoires Merck Sharp & Dohme - Chibret

Study of MK-3475 in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM6)

Dijon : GSK Investigational Site

Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma

Grenoble : GSK Investigational Site

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Kremlin Bicetre : Gustave Roussy Institute

Safety and Efficacy Study of Electrotransfer of Plasmid AMEP to Treat Advanced or Metastatic Melanoma

Lille :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Lille : GSK Investigational Site

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Lille : Centre Oscar Lambret

DNA Repair Inhibitor & Irradiation on Melanoma

Lille : GSK Investigational Site

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

Lille : GSK Investigational Site

Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma

Lyon Cedex 08 : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Marseille : Hôpital Sainte Marguerite

A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Dacarbazine in the Treatment of Patients With Non-Resectable or Metastatic Stage 3 or Stage 4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of C-Kit

Marseille : Hôpital de la Timone

DNA Repair Inhibitor & Irradiation on Melanoma

Marseille cedex 5 : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Marseille cedex 5 : GSK Investigational Site

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

Marseille Cedex 5 : GSK Investigational Site

Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma

Montauban : Local Institution

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Montivilliers : Local Institution

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Montpellier : GSK Investigational Site

Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma

Montpellier cedex 5 : GSK Investigational Site

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Nantes : GSK Investigational Site

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Nantes : Hôpital hôtel-Dieu

DNA Repair Inhibitor & Irradiation on Melanoma

Nantes : GSK Investigational Site

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

Nantes : GSK Investigational Site

Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma

Nantes : Centre Hospitalier Universitaire de Nantes

Relevance of Imiquimod as Neo-adjuvant Treatment to Reduce Excision Size and the Risk of Intralesional Excision in Lentigo Malignant of the Face

Nice :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Nice : GSK Investigational Site

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Paris : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Paris :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Paris : Hôpital Saint-Louis

DNA Repair Inhibitor & Irradiation on Melanoma

Paris : Institut Curie

DNA Repair Inhibitor & Irradiation on Melanoma

Paris : Groupe Hospitalier Cochin - Hôtel Dieu-Broca

DNA Repair Inhibitor & Irradiation on Melanoma

Paris : Novartis Investigative Site

Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients

Paris Cedex 10 : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Paris cedex 18 : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Quimper : Local Institution

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Reims Cedex : GSK Investigational Site

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Rennes : Centre Eugène Marquis

cKIT, BRAF/NRAS Mutations in Advanced Melanoma : Clinical Outcome in Response to Tyrosine-kinase Inhibitors - KitMel Project

Rennes : Rennes University Hospital

cKIT, BRAF/NRAS Mutations in Advanced Melanoma : Clinical Outcome in Response to Tyrosine-kinase Inhibitors - KitMel Project

Rennes : GSK Investigational Site

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

Rennes Cedex : GSK Investigational Site

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Toulouse Cedex : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Toulouse Cedex 3 : Novartis Investigative Site

A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma

Toulouse Cedex 3 : Novartis Investigative Site

A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors

Vandoeuvre les Nancy : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Vandoeuvre les Nancy : GSK Investigational Site

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

Villejuif Cedex : Novartis Investigative Site

A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma

Villejuif cedex : GSK Investigational Site

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Aachen : Dept of Dermatology, University of Aachen

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Augsburg : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Augsburg : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Berlin : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Berlin : Dept of Dermatology, University of Berlin Charite

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

View More »

Berlin : GSK Investigational Site

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

Bochum : Dept of Dermatology, University of Bochum

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Bonn : Neurologische Universitaetsklinik Bonn

A Clinical Trial to Assess the Safety & Efficacy of the Treatment of Patients With Metastasis From Malignant Melanoma - Treatment Consists of the Substances Lomustine (Capsules) & Cytarabine (Injected Into an Area Near the Spinal Cord), Accompanied by Radiotherapy of the Brain

Bonn : Medizinisches Zentrum Bonn Friedensplatz

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Buxtehude : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Erfurt : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Erlangen : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Essen : Novartis Investigative Site

A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

Essen : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Essen :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Essen : Dept of Dermatology, University of Essen

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Essen : GSK Investigational Site

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

Essen : Medizinische Fakultät der Universität Duisburg-Essen

RBL001/RBL002 Phase I Clinical Trial

Frankfurt :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Frankfurt / Main : Dept of Dermatology, University of Frankfurt

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Frankfurt/Oder : Dermatology, Klinikum Frankfurt/Oder

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Freiburg : GSK Investigational Site

Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma

Freiburg : University Medical Center Freiburg, Department of Dermatology

Quality of Life and Psychological Well-being in Patients With Malignant Melanoma

Gera : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Hannover : Local Institution

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Hannover : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Hannover : Dept of Dermatology, University of Hannover

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Hannover : GSK Investigational Site

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

Hannover : GSK Investigational Site

Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma

Heidelberg : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Heidelberg : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Homburg : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Homburg : GSK Investigational Site

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

Homburg/Saar : Dept of Dermatology, Saarland University

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Jena : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Jena :

A Study of RO5185426 in Patients With Metastatic Melanoma

Jena : Dept of Dermatology, University of Jena

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Jena : GSK Investigational Site

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

Kiel : Novartis Investigative Site

A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

Kiel : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Kiel : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Kiel :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Kiel : Dept of Dermatology, University of Schleswig-Holstein Campus Kiel

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Kiel : GSK Investigational Site

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

Kiel : GSK Investigational Site

Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma

Koeln : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Koeln : GSK Investigational Site

Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma

Köln : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Köln : University Medical Center Collogne, Department of Dermatology

Quality of Life and Psychological Well-being in Patients With Malignant Melanoma

Leipzig : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Ludwigshafen : Dermatology, Klinikum Ludwishafen

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Luebeck : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Luebeck : Dept of Dermatology, University of Schleswig-Holstein Campus Luebeck

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Luebeck : GSK Investigational Site

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

Magdeburg : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Magdeburg : Dept of Dermatology, Univeristy of Magdeburg

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Mainz : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Mainz : Dept of Dermatology, University of Mainz

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Mainz : GSK Investigational Site

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

Mainz : Universtitätsmedizin der Johannes-Gutenberg Universtität

RBL001/RBL002 Phase I Clinical Trial

Manheim : Local Institution

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Mannheim : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Mannheim :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Mannheim : Dept of Dermatology, University of Mannheim

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Mannheim : GSK Investigational Site

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

Mannheim : GSK Investigational Site

Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma

Marburg : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Marburg : Dept of Dermatology, University of Marburg

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Muenchen : Novartis Investigative Site

A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

Muenchen : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Muenchen : Dept of Dermatology, University of Muenchen

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Muenster : Dept of Dermatology, University of Muenster

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Muenster : Dept of Medical Oncology, Fachklinik Hornheide

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Münster :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Nuernberg : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Nuernberg : GSK Investigational Site

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

Quedlinburg : Dermatology, Klinikum Dorothea Christiane Erxleben

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Regensburg : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Regensburg : GSK Investigational Site

Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma

Tübingen : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Tübingen :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Tuebingen : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Tuebingen : Dept of Dermatology, University of Tuebingen

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Tuebingen : GSK Investigational Site

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

Tuebingen : GSK Investigational Site

Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma

Ulm : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Wiesbaden :

A Study of RO5185426 in Patients With Metastatic Melanoma

Wuerzburg : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Wuerzburg : Dept of Dermatology, University of Wuerzburg

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Wuerzburg : GSK Investigational Site

Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma

Athens : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Athens :

A Study of RO5185426 in Patients With Metastatic Melanoma

Heraklion :

A Study of RO5185426 in Patients With Metastatic Melanoma

N. Faliro : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Thessaloniki : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Debrecen : GSK Investigational Site

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Szeged : GSK Investigational Site

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Hyderabad :

A Study of RO5185426 in Patients With Metastatic Melanoma

Lucknow :

A Study of RO5185426 in Patients With Metastatic Melanoma

Nashik :

A Study of RO5185426 in Patients With Metastatic Melanoma

New Delhi :

A Study of RO5185426 in Patients With Metastatic Melanoma

Trivandrum :

A Study of RO5185426 in Patients With Metastatic Melanoma

View More »

Vellore :

A Study of RO5185426 in Patients With Metastatic Melanoma

Co.Cork : GSK Investigational Site

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Cork : Local Institution

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Cork :

A Study of RO5185426 in Patients With Metastatic Melanoma

Dublin :

A Study of RO5185426 in Patients With Metastatic Melanoma

Dublin : GSK Investigational Site

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

View More »

Galway :

A Study of RO5185426 in Patients With Metastatic Melanoma

Limerick :

A Study of RO5185426 in Patients With Metastatic Melanoma

Tullamore : Local Institution

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Waterford :

A Study of RO5185426 in Patients With Metastatic Melanoma

Haifa : Local Institution

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Hod Hasharon : Merck Sharp & Dohme Co. Ltd. Updated

Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)

Jerusalem : Local Institution

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Jerusalem : GSK Investigational Site

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Jerusalem : Oncology institute, Shaare Zedek Medical Center

IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma

View More »

Ramat Gan : GSK Investigational Site

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Tel Hashomer : Ella Institute, Oncology institute, Sheba Medical Center

IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma

Tel Hashomer : Oncology Institute, Sheba Medical Center

IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma

Tel-hashomer :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Bari :

A Study of RO5185426 in Patients With Metastatic Melanoma

Bergamo : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Bergamo :

A Study of RO5185426 in Patients With Metastatic Melanoma

Brescia :

A Study of RO5185426 in Patients With Metastatic Melanoma

Candiolo (TO) : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

View More »

Firenze :

A Study of RO5185426 in Patients With Metastatic Melanoma

Genova : Novartis Investigative Site

A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

Genova : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Genova :

A Study of RO5185426 in Patients With Metastatic Melanoma

Genova : GSK Investigational Site

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

Meldola :

A Study of RO5185426 in Patients With Metastatic Melanoma

Meldola (FC) : GSK Investigational Site

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

Milano : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Milano :

A Study of RO5185426 in Patients With Metastatic Melanoma

Milano : GSK Investigational Site

Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma

Milano : GSK Investigational Site

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

Milano : GSK Investigational Site

Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma

Napoli : Novartis Investigative Site

A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

Napoli :

A Study of RO5185426 in Patients With Metastatic Melanoma

Napoli : GSK Investigational Site

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Napoli : GSK Investigational Site

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

Padova : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Padova :

A Study of RO5185426 in Patients With Metastatic Melanoma

Padova : GSK Investigational Site

Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma

Pisa :

A Study of RO5185426 in Patients With Metastatic Melanoma

Ravenna : GSK Investigational Site

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

Rimini : GSK Investigational Site

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

Roma : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Roma :

A Study of RO5185426 in Patients With Metastatic Melanoma

Rozzano (MI) : GSK Investigational Site

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

Siena :

A Study of RO5185426 in Patients With Metastatic Melanoma

Siena :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Siena : GSK Investigational Site

Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma

Udine :

A Study of RO5185426 in Patients With Metastatic Melanoma

Chuo-ku : Local Institution

Phase 2 Study of Ipilimumab Plus DTIC in Japanese Advanced Melanoma Patients

Seoul :

A Study of RO5185426 in Patients With Metastatic Melanoma

Klaipeda :

A Study of RO5185426 in Patients With Metastatic Melanoma

Vilnius :

A Study of RO5185426 in Patients With Metastatic Melanoma

Skopje :

A Study of RO5185426 in Patients With Metastatic Melanoma

Leon :

A Study of RO5185426 in Patients With Metastatic Melanoma

Mexico City :

A Study of RO5185426 in Patients With Metastatic Melanoma

Amsterdam : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Amsterdam :

A Study of RO5185426 in Patients With Metastatic Melanoma

Amsterdam :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Amsterdam : Antoni van Leeuwenhoek Ziekenhuis

An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.

Amsterdam : Vrije Universiteit medisch centrum (Vumc)

An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.

View More »

Amsterdam : GSK Investigational Site

Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma

Blaricum :

A Study of RO5185426 in Patients With Metastatic Melanoma

Breda :

A Study of RO5185426 in Patients With Metastatic Melanoma

Groningen :

A Study of RO5185426 in Patients With Metastatic Melanoma

Groningen :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Leiden : Leids Universitair Medisch Centrum (LUMC)

An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.

Leiden : GSK Investigational Site

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Leiden : Novartis Investigative Site

Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients

Maastricht :

A Study of RO5185426 in Patients With Metastatic Melanoma

Maastricht : Maastricht Universitair Medisch Centrum

An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.

Maastricht : GSK Investigational Site

Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma

Rotterdam : Novartis Investigative Site

A Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands

Rotterdam : Erasmus MC

An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.

Rotterdam : GSK Investigational Site

Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma

Zwolle : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Newtown, Wellington : GSK Investigational Site

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Bergen :

A Study of RO5185426 in Patients With Metastatic Melanoma

Drammen : MSD (Norge) AS Updated

Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)

Kristiansand : GSK Investigational Site

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Oslo : Novartis Investigative Site

A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma

Oslo :

A Study of RO5185426 in Patients With Metastatic Melanoma

View More »

Oslo : GSK Investigational Site

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Arequipa :

A Study of RO5185426 in Patients With Metastatic Melanoma

Lima :

A Study of RO5185426 in Patients With Metastatic Melanoma

Gdansk : GSK Investigational Site

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Gdansk : GSK Investigational Site

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

Konin : GSK Investigational Site

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Poznan : WCO (Great Poland Cancer Centre)

Safety and Pharmacodynamic Study of a New Formulation, AGI - 101H Vaccine in the Treatment of Advanced Melanoma

Porto :

A Study of RO5185426 in Patients With Metastatic Melanoma

Timisoara :

A Study of RO5185426 in Patients With Metastatic Melanoma

Chelyabinsk : GSK Investigational Site

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

Kazan : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Moscow : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Moscow : GSK Investigational Site

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

Pyatigorsk : GSK Investigational Site

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

View More »

St. Petersburg : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

St. Petersburg : GSK Investigational Site

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

Stavropol : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Belgrade :

A Study of RO5185426 in Patients With Metastatic Melanoma

Ljubljana :

A Study of RO5185426 in Patients With Metastatic Melanoma

Ljubljana : Institute of Oncology Ljubljana

Safety and Efficacy Study of Electrotransfer of Plasmid AMEP to Treat Advanced or Metastatic Melanoma

Bloemfontein :

A Study of RO5185426 in Patients With Metastatic Melanoma

Cape Town :

A Study of RO5185426 in Patients With Metastatic Melanoma

Johannesburg :

A Study of RO5185426 in Patients With Metastatic Melanoma

Pretoria :

A Study of RO5185426 in Patients With Metastatic Melanoma

Barcelona : Novartis Investigative Site

A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma

Barcelona : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Barcelona : Novartis Investigative Site

A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors

Barcelona : Novartis Investigative Site

A Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands

Barcelona :

A Study of RO5185426 in Patients With Metastatic Melanoma

View More »

Barcelona :

A Study of RO5212054 (PLX3603) in Patients With BRAF V600-mutated Advanced Solid Tumours

Barcelona :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Cartagena (murcia) :

A Study of RO5185426 in Patients With Metastatic Melanoma

Cordoba :

A Study of RO5185426 in Patients With Metastatic Melanoma

Granada :

A Study of RO5185426 in Patients With Metastatic Melanoma

Hospitalet de Llobregat, Barcelona : GSK Investigational Site

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

La Coruna :

A Study of RO5185426 in Patients With Metastatic Melanoma

La Laguna (tenerife) :

A Study of RO5185426 in Patients With Metastatic Melanoma

Las Palmas de Gran Canaria :

A Study of RO5185426 in Patients With Metastatic Melanoma

Leon :

A Study of RO5185426 in Patients With Metastatic Melanoma

Madrid : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Madrid :

A Study of RO5185426 in Patients With Metastatic Melanoma

Madrid :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Madrid : GSK Investigational Site

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Malaga :

A Study of RO5185426 in Patients With Metastatic Melanoma

Málaga :

A Study of RO5185426 in Patients With Metastatic Melanoma

Palma de Mallorca :

A Study of RO5185426 in Patients With Metastatic Melanoma

Pamplona : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Pamplona :

A Study of RO5185426 in Patients With Metastatic Melanoma

Pamplona :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Pamplona : Local Institution

Phase 1 Biomarker Study of Anti-PD-1 in Advanced Melanoma

Salamanca :

A Study of RO5185426 in Patients With Metastatic Melanoma

Santander :

A Study of RO5185426 in Patients With Metastatic Melanoma

Sevilla :

A Study of RO5185426 in Patients With Metastatic Melanoma

Valencia : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Valencia :

A Study of RO5185426 in Patients With Metastatic Melanoma

Vigo :

A Study of RO5185426 in Patients With Metastatic Melanoma

Zaragoza :

A Study of RO5185426 in Patients With Metastatic Melanoma

Goteborg : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Göteborg : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Linköping : GSK Investigational Site

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Lund : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Lund : Lunds Universitetssjukhus

SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma

View More »

Malmö : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Stockholm : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Stockholm : Södersjukhuset

SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma

Stockholm : Karolinska Sjukhuset

SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma

Umeå : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Umeå : GSK Investigational Site

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Umeå : Norrlands Universitetssjukhus

SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma

Uppsala : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Uppsala : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Genève : GSK Investigational Site

Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma

Lausanne : GSK Investigational Site

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Lausanne : Multidisciplinary Oncology Center, CHUV

Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients

Lugano : Local Institution

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Zuerich : Novartis Investigative Site

A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma

View More »

Zürich : Local Institution

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Zürich : GSK Investigational Site

Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma

Bangkok : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Songkla : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Adana :

A Study of RO5185426 in Patients With Metastatic Melanoma

Ankara :

A Study of RO5185426 in Patients With Metastatic Melanoma

Antalya :

A Study of RO5185426 in Patients With Metastatic Melanoma

Gaziantep :

A Study of RO5185426 in Patients With Metastatic Melanoma

Istanbul :

A Study of RO5185426 in Patients With Metastatic Melanoma

View More »

Izmir :

A Study of RO5185426 in Patients With Metastatic Melanoma

Dnipropetrovsk : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Kyiv : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Lviv : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Sumy : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Bebington : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Birmingham : Queen Elizabeth Hospital

Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma

Cambridge : Local Institution

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Cambridge :

A Study of RO5185426 in Patients With Metastatic Melanoma

Cambridge : GSK Investigational Site

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

View More »

Cambridge : Cambridge University Hospitals NHS Foundation Trust

HYPAZ: Hypertension Induced by Pazopanib

Cambridge : Addenbrooke's Hospital

Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma

Chelmsford : GSK Investigational Site

Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma

Edgbaston, Birmingham : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Glasgow :

A Study of RO5185426 in Patients With Metastatic Melanoma

Glasgow : GSK Investigational Site

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Glasgow : The Beatson Institute

Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma

Leeds : Local Institution

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Leeds : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Leeds :

A Study of RO5185426 in Patients With Metastatic Melanoma

Leeds : St James' Institute of Oncology

Study of a DNA Immunotherapy to Treat Melanoma

Leeds : St James Hospital

Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma

Leicester : GSK Investigational Site

Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma

London : Local Institution

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

London : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

London :

A Study of RO5185426 in Patients With Metastatic Melanoma

London : King's College London Guy's Hospital Campus

An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors

London : GSK Investigational Site

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

London : Novartis Investigative Site

Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients

Manchester :

A Study of RO5185426 in Patients With Metastatic Melanoma

Manchester : GSK Investigational Site

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Manchester : Christie Hospital

Study of a DNA Immunotherapy to Treat Melanoma

Newcastle upon Tyne : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Newcastle Upon Tyne :

A Study of RO5185426 in Patients With Metastatic Melanoma

Newcastle Upon Tyne and Wear : Newcastle Upon Tyne NHS Foundation Trust

An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors

Newcastle-upon-Tyne : Northern Centre for Cancer Care, Freeman Hospital

Study of a DNA Immunotherapy to Treat Melanoma

Northwood : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Northwood :

A Study of RO5185426 in Patients With Metastatic Melanoma

Northwood :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Nottingham : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Nottingham :

A Study of RO5185426 in Patients With Metastatic Melanoma

Nottingham : Department of Clinical Oncology, City Hospital

Study of a DNA Immunotherapy to Treat Melanoma

Oxford : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Oxford :

A Study of RO5185426 in Patients With Metastatic Melanoma

Oxford : NIHR Biomedical Research Centre

Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma

Preston : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Southampton :

A Study of RO5185426 in Patients With Metastatic Melanoma

Southampton : GSK Investigational Site

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Southampton : GSK Investigational Site

Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma

Southampton : Department of Medical Oncology, Southampton General Hospital

Study of a DNA Immunotherapy to Treat Melanoma

Sutton : GSK Investigational Site

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Swansea :

A Study of RO5185426 in Patients With Metastatic Melanoma

Swansea : GSK Investigational Site

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Truro, Cornwall : Local Institution

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Wirral : Clatterbridge Centre for Oncology NHS Foundation Trust

A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma